TITLE

Bridging Innate and Adaptive Antitumor Immunity Targeting Glycans

AUTHOR(S)
Pashov, Anastas; Monzavi-Karbassi, Bejatolah; Raghava, Gajendra P. S.; Kieber-Emmons, Thomas
PUB. DATE
January 2010
SOURCE
Journal of Biomedicine & Biotechnology;2010, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Effective immunotherapy for cancer depends on cellular responses to tumor antigens. The role of major histocompatibility complex (MHC) in T-cell recognition and T-cell receptor repertoire selection has become a central tenet in immunology. Structurally, this does not contradict earlier findings that T-cells can differentiate between small hapten structures like simple glycans. Understanding T-cell recognition of antigens as defined genetically by MHC and combinatorially by T cell receptors led to the "altered self " hypothesis. This notion reflects a more fundamental principle underlying immune surveillance and integrating evolutionarily and mechanistically diverse elements of the immune system. Danger associated molecular patterns, including those generated by glycan remodeling, represent an instance of altered self. A prominent example is the modification of the tumorassociated antigen MUC1. Similar examples emphasize glycan reactivity patterns of antigen receptors as a phenomenon bridging innate and adaptive but also humoral and cellular immunity and providing templates for immunotherapies.
ACCESSION #
53271073

 

Related Articles

  • Characterization of MHC Ligands for Peptide Based Tumor Vaccination. Klug, Felix; Miller, Matthias; Schmidt, Hans-Henning; Stevanović, Stefan // Current Pharmaceutical Design;10/1/2009, Vol. 15 Issue 28, p3221 

    Short peptides derived from cellular proteins may escape complete destruction during protein catabolism and finally serve as a showcase in the immune system. Exposed at the cell surface to scrutiny by T cells, MHC:peptide complexes mediate a highly specific and immediate information transfer...

  • Adaptive immunity in cancer immunology and therapeutics. Spurrell, Emma L.; Lockley, Michelle // Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1 

    The vast genetic alterations characteristic of tumours produce a number of tumour antigens that enable the immune system to differentiate tumour cells from normal cells. Counter to this, tumour cells have developed mechanisms by which to evade host immunity in their constant quest for growth and...

  • Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Kreiter, Sebastian; Vormehr, Mathias; van de Roemer, Niels; Diken, Mustafa; Löwer, Martin; Diekmann, Jan; Boegel, Sebastian; Schrörs, Barbara; Vascotto, Fulvia; Castle, John C.; Tadmor, Arbel D.; Schoenberger, Stephen P.; Huber, Christoph; Türeci, Özlem; Sahin, Ugur // Nature;4/30/2015, Vol. 520 Issue 7549, p692 

    Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every...

  • A vaccine targeting mutant IDH1 induces antitumour immunity. Schumacher, Theresa; Bunse, Lukas; Pusch, Stefan; Sahm, Felix; Wiestler, Benedikt; Quandt, Jasmin; Menn, Oliver; Osswald, Matthias; Oezen, Iris; Ott, Martina; Keil, Melanie; Balß, Jörg; Rauschenbach, Katharina; Grabowska, Agnieszka K.; Vogler, Isabel; Diekmann, Jan; Trautwein, Nico; Eichmüller, Stefan B.; Okun, Jürgen; Stevanović, Stefan // Nature;8/21/2014, Vol. 512 Issue 7514, p324 

    Monoallelic point mutations of isocitrate dehydrogenase type 1 (IDH1) are an early and defining event in the development of a subgroup of gliomas and other types of tumour. They almost uniformly occur in the critical arginine residue (Arg 132) in the catalytic pocket, resulting in a neomorphic...

  • Marked Differences in Human Melanoma Antigen-Specific T Cell Responsiveness after Vaccination Using a Functional Microarray. Chen, Daniel S.; Soen, Yoav; Stuge, Tor B.; Lee, Peter P.; Weber, Jeffrey S.; Brown, Patrick O.; Davis, Mark M. // PLoS Medicine;Oct2005, Vol. 2 Issue 10, p1018 

    Background: In contrast to many animal model studies, immunotherapeutic trials in humans suffering from cancer invariably result in a broad range of outcomes, from long-lasting remissions to no discernable effect. Methods and Findings: In order to study the T cell responses in patients...

  • Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation. Xianghui He; Tsang, Tom C; Luo, Phoebe; Tong Zhang; Harris, David T // Cancer Gene Therapy;Sep2003, Vol. 10 Issue 9, p669 

    The density of tumor antigen in conjunction with major histocompatibility complex (MHC) class I molecules on the cell surface affects cytotoxic T cell (CTL) function in an active antitumor immune response. Thus, methods to enhance antigen expression/presentation could augment the effect of...

  • The footprint of a killer. Karre, Klas; Schneider, Gunter // Nature;6/1/2000, Vol. 405 Issue 6786, p527 

    Discusses a study that investigates the effect of major histocompatibility complex (MHC) receptors on natural killer (NK) cells. Function of MHC class I molecules in the immune system; expression of MHC; Description of an immunoglobulin-type receptor, KIR2DL2, which is the focus of the study;...

  • Immunology highlights from the recent literature.  // Nature Immunology;Sep2002, Vol. 3 Issue 9, p805 

    Presents news items related to immunology, as of September 2002. Possible use of T cells in HIV treatment; Retograde transit of complexes of peptide and Major Histocompatibility Complex in antigen presentation by MHC class II; Role of NKG2D receptors in different immune cell types.

  • The repertoires of peptides presented by MHC-II in the thymus and in peripheral tissue: a clue for autoimmunity? Collado, Javier A.; Guitart, Carolina; Ciudad, M. Teresa; Alvarez, Iñaki; Jaraquemada, Dolores // Frontiers in Immunology;Dec2013, Vol. 4, p1 

    T-cell tolerance to self-antigens is established in the thymus through the recognition by developing thymocytes of self-peptide-MHC complexes and induced and maintained in the periphery. Efficient negative selection of auto-reactive T cells in the thymus is dependent on the in situ expression of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics